Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Persistence Pays Off for Tacere Execs

This article was originally published in Start Up

Executive Summary

RNAi firm Tacere's deal with Pfizer demonstrates pharmaceutical companies' interest in exploring a variety of RNA interference techniques as well as the rewards sometimes associated with the dogged development of a single project.
Advertisement

Related Content

Gene Therapy: The Next Big Thing?
Gene Therapy: The Next Big Thing?
Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate
In RNAi, Technology Proliferates Beyond the Big Two
In RNAi, Technology Proliferates Beyond the Big Two

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel